Cathepsin K Inhibitors: A Unique Mechanism of Action for the Treatment of Osteoporosis (Slides with Transcript) medscape.org/viewarticle/588253 The bone resorptive process involves two stages: (1) the dissolution (i.e., dissolving away) of mineral by the secretion of acid into the microenvironment underneath the active osteoclast, and (2) the dissolution of the collagen or bone matrix, and thats done by a class of specific proteases called cathepsins. Cathepsin K is a member of that family of proteases that is relatively specific to the dissolution of type 1 or bone collagen. Odanacatib is a cathepsin K inhibitor. Merck & Co announced on September 15, 2014, that it expects to seek U.S. approval in 2015 for its experimental osteoporosis drug, odanacatib, after the once-weekly medicine met its primary goals in a late-stage trial. Read this article for information about the drug’s mechanism of action.
Posted on: Wed, 17 Sep 2014 15:17:02 +0000
Trending Topics
Recently Viewed Topics
© 2015